Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of bomedemstat versus best available therapy in hydroxyurea-resistant or -intolerant essential thrombocythemia
MOH_2023-11-21_013049Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bomedemstat in thrombocythemia (2 arms), sponsored by Merck & Co. Started Nov 2023; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on MOH_2023-11-21_013049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-21_013049.